Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,237 | -9,197 | -5,357 | -17,129 | -11,921 |
| Depreciation Amortization | 162 | 98 | 44 | 177 | 130 |
| Accounts receivable | -308 | -795 | -430 | 360 | -447 |
| Accounts payable and accrued liabilities | -510 | -74 | -183 | 185 | 669 |
| Other Working Capital | -384 | -1,083 | -403 | 571 | 791 |
| Other Operating Activity | 4,687 | 4,372 | 2,340 | 3,104 | 2,423 |
| Operating Cash Flow | $-8,590 | $-6,679 | $-3,989 | $-12,732 | $-8,355 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -289 | -233 | -24 | -183 | -159 |
| Investing Cash Flow | $-289 | $-233 | $-24 | $-183 | $-159 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,229 | 951 | 764 | 28,874 | 28,874 |
| Other Financing Activity | -34 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $1,195 | $951 | $764 | $28,874 | $28,874 |
| Beginning Cash Position | 22,390 | 22,390 | 22,390 | 6,431 | 6,431 |
| End Cash Position | 14,706 | 16,429 | 19,141 | 22,390 | 26,791 |
| Net Cash Flow | $-7,684 | $-5,961 | $-3,249 | $15,959 | $20,360 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,590 | -6,679 | -3,989 | -12,732 | -8,355 |
| Capital Expenditure | -289 | -233 | -24 | -186 | -159 |
| Free Cash Flow | -8,879 | -6,912 | -4,013 | -12,918 | -8,514 |